Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 666

1.

Comparison on epidemiology, tumor location, histology, and prognosis of intracranial germ cell tumors between Mayo Clinic and Japanese consortium cohorts.

Takami H, Perry A, Graffeo CS, Giannini C, Narita Y, Nakazato Y, Saito N, Nishikawa R, Matsutani M, Ichimura K, Daniels DJ.

J Neurosurg. 2020 Jan 31:1-11. doi: 10.3171/2019.11.JNS191576. [Epub ahead of print]

PMID:
32005022
2.

[A Case of Familial Schwannomatosis Occurring as Intraorbital Schwannoma].

Miyasaka K, Shibahara I, Hide T, Inukai M, Saegusa M, Nakano Y, Ichimura K, Takaso M, Kumabe T.

No Shinkei Geka. 2020 Jan;48(1):71-77. doi: 10.11477/mf.1436204137. Japanese.

PMID:
31983691
3.

Automatic Measurements of Neck Angles toward the Bedside Treatment for the Dysphagia Patients at the Community-Based Health Care.

Kuramoto N, Ichimura K, Jayatilake D, Hidaka K, Suzuki K.

Conf Proc IEEE Eng Med Biol Soc. 2019 Jul;2019:595-598. doi: 10.1109/EMBC.2019.8857417.

PMID:
31945968
4.

Prediction of IDH and TERT promoter mutations in low-grade glioma from magnetic resonance images using a convolutional neural network.

Fukuma R, Yanagisawa T, Kinoshita M, Shinozaki T, Arita H, Kawaguchi A, Takahashi M, Narita Y, Terakawa Y, Tsuyuguchi N, Okita Y, Nonaka M, Moriuchi S, Takagaki M, Fujimoto Y, Fukai J, Izumoto S, Ishibashi K, Nakajima Y, Shofuda T, Kanematsu D, Yoshioka E, Kodama Y, Mano M, Mori K, Ichimura K, Kanemura Y, Kishima H.

Sci Rep. 2019 Dec 30;9(1):20311. doi: 10.1038/s41598-019-56767-3.

5.

Spinal cord astroblastoma with an EWSR1-BEND2 fusion classified as a high-grade neuroepithelial tumour with MN1 alteration.

Yamasaki K, Nakano Y, Nobusawa S, Okuhiro Y, Fukushima H, Inoue T, Murakami C, Hirato J, Kunihiro N, Matsusaka Y, Honda-Kitahara M, Ozawa T, Shiraishi K, Kohno T, Ichimura K, Hara J.

Neuropathol Appl Neurobiol. 2019 Dec 21. doi: 10.1111/nan.12593. [Epub ahead of print] No abstract available.

PMID:
31863478
6.

Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study.

Li BK, Vasiljevic A, Dufour C, Yao F, Ho BLB, Lu M, Hwang EI, Gururangan S, Hansford JR, Fouladi M, Nobusawa S, Laquerriere A, Delisle MB, Fangusaro J, Forest F, Toledano H, Solano-Paez P, Leary S, Birks D, Hoffman LM, Szathmari A, Faure-Conter C, Fan X, Catchpoole D, Zhou L, Schultz KAP, Ichimura K, Gauchotte G, Jabado N, Jones C, Loussouarn D, Mokhtari K, Rousseau A, Ziegler DS, Tanaka S, Pomeroy SL, Gajjar A, Ramaswamy V, Hawkins C, Grundy RG, Hill DA, Bouffet E, Huang A, Jouvet A.

Acta Neuropathol. 2020 Feb;139(2):223-241. doi: 10.1007/s00401-019-02111-y. Epub 2019 Dec 9.

PMID:
31820118
7.

Anticancer Non-narcotic Opium Alkaloid Papaverine Suppresses Human Glioblastoma Cell Growth.

Inada M, Sato A, Shindo M, Yamamoto Y, Akasaki Y, Ichimura K, Tanuma SI.

Anticancer Res. 2019 Dec;39(12):6743-6750. doi: 10.21873/anticanres.13889.

PMID:
31810939
8.

Assessment of the Diagnostic Utility of Serum MicroRNA Classification in Patients With Diffuse Glioma.

Ohno M, Matsuzaki J, Kawauchi J, Aoki Y, Miura J, Takizawa S, Kato K, Sakamoto H, Matsushita Y, Takahashi M, Miyakita Y, Ichimura K, Narita Y, Ochiya T.

JAMA Netw Open. 2019 Dec 2;2(12):e1916953. doi: 10.1001/jamanetworkopen.2019.16953.

9.

A multicenter randomized phase III study for newly diagnosed maximally resected glioblastoma comparing carmustine wafer implantation followed by chemoradiotherapy with temozolomide with chemoradiotherapy alone; Japan Clinical Oncology Group Study JCOG1703 (MACS study).

Kadota T, Saito R, Kumabe T, Mizusawa J, Katayama H, Sumi M, Igaki H, Kinoshita M, Komori T, Ichimura K, Narita Y, Nishikawa R.

Jpn J Clin Oncol. 2019 Dec 27;49(12):1172-1175. doi: 10.1093/jjco/hyz169.

PMID:
31804699
10.

Three-dimensional imaging of podocyte ultrastructure using FE-SEM and FIB-SEM tomography.

Miyaki T, Kawasaki Y, Hosoyamada Y, Amari T, Kinoshita M, Matsuda H, Kakuta S, Sakai T, Ichimura K.

Cell Tissue Res. 2020 Feb;379(2):245-254. doi: 10.1007/s00441-019-03118-3. Epub 2019 Nov 22. Review.

PMID:
31758252
11.

Delineating the molecular and histological events that govern right ventricular recovery using a novel mouse model of PA de-banding.

Boehm M, Tian X, Mao Y, Ichimura K, Dufva MJ, Ali K, Prosseda SD, Shi Y, Kuramoto K, Reddy S, Kheyfets VO, Metzger RJ, Spiekerkoetter E.

Cardiovasc Res. 2019 Nov 18. pii: cvz310. doi: 10.1093/cvr/cvz310. [Epub ahead of print]

PMID:
31738411
12.

A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model.

Machida Y, Nakagawa M, Matsunaga H, Yamaguchi M, Ogawara Y, Shima Y, Yamagata K, Katsumoto T, Hattori A, Itoh M, Seki T, Nishiya Y, Nakamura K, Suzuki K, Imaoka T, Baba D, Suzuki M, Sampetrean O, Saya H, Ichimura K, Kitabayashi I.

Mol Cancer Ther. 2020 Feb;19(2):375-383. doi: 10.1158/1535-7163.MCT-18-1349. Epub 2019 Nov 14.

PMID:
31727689
13.

Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.

Ohno M, Miyakita Y, Takahashi M, Igaki H, Matsushita Y, Ichimura K, Narita Y.

Radiat Oncol. 2019 Nov 12;14(1):200. doi: 10.1186/s13014-019-1389-7.

14.

Changes of absorbed dose rate in air in metropolitan Tokyo relating to radiocesium released from the Fukushima Daiichi Nuclear Power Plant accident: Results of a five-year study.

Inoue K, Tsuruoka H, Shimizu H, Arai M, Veerasamy N, Tsukada M, Ichimura K, Nakazawa S, Taguchi Y, Fukushi M.

PLoS One. 2019 Oct 24;14(10):e0224449. doi: 10.1371/journal.pone.0224449. eCollection 2019.

15.

Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas.

Guerreiro Stucklin AS, Ryall S, Fukuoka K, Zapotocky M, Lassaletta A, Li C, Bridge T, Kim B, Arnoldo A, Kowalski PE, Zhong Y, Johnson M, Li C, Ramani AK, Siddaway R, Nobre LF, de Antonellis P, Dunham C, Cheng S, Boué DR, Finlay JL, Coven SL, de Prada I, Perez-Somarriba M, Faria CC, Grotzer MA, Rushing E, Sumerauer D, Zamecnik J, Krskova L, Garcia Ariza M, Cruz O, Morales La Madrid A, Solano P, Terashima K, Nakano Y, Ichimura K, Nagane M, Sakamoto H, Gil-da-Costa MJ, Silva R, Johnston DL, Michaud J, Wilson B, van Landeghem FKH, Oviedo A, McNeely PD, Crooks B, Fried I, Zhukova N, Hansford JR, Nageswararao A, Garzia L, Shago M, Brudno M, Irwin MS, Bartels U, Ramaswamy V, Bouffet E, Taylor MD, Tabori U, Hawkins C.

Nat Commun. 2019 Sep 25;10(1):4343. doi: 10.1038/s41467-019-12187-5.

16.

Subependymal giant cell astrocytoma harboring a PRRC2B-ALK fusion: A case report.

Tsurubuchi T, Nakano Y, Hirato J, Yoshida A, Muroi A, Sakamoto N, Alexander Z, Matsuda M, Ishikawa E, Kohno T, Yoshioka T, Honda-Kitahara M, Ichimura K, Yamamoto T, Matsumura A.

Pediatr Blood Cancer. 2019 Dec;66(12):e27995. doi: 10.1002/pbc.27995. Epub 2019 Sep 10. No abstract available.

PMID:
31502411
17.

Two cases of primary supratentorial intracranial rhabdomyosarcoma with DICER1 mutation which may belong to a "spindle cell sarcoma with rhabdomyosarcoma-like feature, DICER1 mutant".

Sakaguchi M, Nakano Y, Honda-Kitahara M, Kinoshita M, Tanaka S, Oishi M, Noguchi K, Fukuda M, Maeba H, Watanabe T, Hayashi Y, Ikeda H, Minato H, Ichimura K, Nojima T, Nakada M.

Brain Tumor Pathol. 2019 Oct;36(4):174-182. doi: 10.1007/s10014-019-00352-z. Epub 2019 Sep 5.

PMID:
31487013
18.

Integrated clinical, histopathological, and molecular data analysis of 190 central nervous system germ cell tumors from the iGCT Consortium.

Takami H, Fukuoka K, Fukushima S, Nakamura T, Mukasa A, Saito N, Yanagisawa T, Nakamura H, Sugiyama K, Kanamori M, Tominaga T, Maehara T, Nakada M, Kanemura Y, Asai A, Takeshima H, Hirose Y, Iuchi T, Nagane M, Yoshimoto K, Matsumura A, Kurozumi K, Nakase H, Sakai K, Tokuyama T, Shibui S, Nakazato Y, Narita Y, Nishikawa R, Matsutani M, Ichimura K.

Neuro Oncol. 2019 Dec 17;21(12):1565-1577. doi: 10.1093/neuonc/noz139.

PMID:
31420671
19.

Histological and genetic analysis of anaplastic pleomorphic xanthoastrocytoma suspected of malignant progression over a 12-year clinical course.

Fukushima H, Nakano Y, Ishii N, Nozuchi N, Okuno T, Yamasaki K, Okada K, Fujisaki H, Kunihiro N, Matsusaka Y, Sakamoto H, Honda-Kitahara M, Ichimura K, Hara J, Inoue T.

Pathol Int. 2019 Oct;69(10):608-613. doi: 10.1111/pin.12840. Epub 2019 Aug 9.

PMID:
31397529
20.

Presacral malignant teratoid neoplasm in association with pathogenic DICER1 variation.

Nakano Y, Hasegawa D, Stewart DR, Schultz KAP, Harris AK, Hirato J, Uemura S, Tamura A, Saito A, Kawamura A, Yoshida M, Yamasaki K, Yamashita S, Ushijima T, Kosaka Y, Ichimura K, Dehner LP, Hill DA.

Mod Pathol. 2019 Dec;32(12):1744-1750. doi: 10.1038/s41379-019-0319-4. Epub 2019 Jul 11.

21.

Absence of H3F3A mutation in a subset of malignant giant cell tumor of bone.

Yoshida KI, Nakano Y, Honda-Kitahara M, Wakai S, Motoi T, Ogura K, Sano N, Shibata T, Okuma T, Iwata S, Kawai A, Ichimura K, Yoshida A.

Mod Pathol. 2019 Dec;32(12):1751-1761. doi: 10.1038/s41379-019-0318-5. Epub 2019 Jul 8.

PMID:
31285528
22.

A long-term survivor of pediatric midline glioma with H3F3A K27M and BRAF V600E double mutations.

Nakano Y, Yamasaki K, Sakamoto H, Matsusaka Y, Kunihiro N, Fukushima H, Inoue T, Honda-Kitahara M, Hara J, Yoshida A, Ichimura K.

Brain Tumor Pathol. 2019 Oct;36(4):162-168. doi: 10.1007/s10014-019-00347-w. Epub 2019 Jun 28.

PMID:
31254135
23.

Polyarteritis Nodosa with Marked Eosinophilia, Associated with Severe Gastrointestinal Tract Involvement and Recurrent Venous Thrombosis.

Oiwa H, Taniguchi K, Miyoshi N, Sasaki K, Ichimura K, Kubota T, Sato D.

Intern Med. 2019 Oct 15;58(20):3051-3055. doi: 10.2169/internalmedicine.2802-19. Epub 2019 Jun 27.

24.

Intratumoural immune cell landscape in germinoma reveals multipotent lineages and exhibits prognostic significance.

Takami H, Fukushima S, Aoki K, Satomi K, Narumi K, Hama N, Matsushita Y, Fukuoka K, Yamasaki K, Nakamura T, Mukasa A, Saito N, Suzuki T, Yanagisawa T, Nakamura H, Sugiyama K, Tamura K, Maehara T, Nakada M, Nonaka M, Asai A, Yokogami K, Takeshima H, Iuchi T, Kanemura Y, Kobayashi K, Nagane M, Kurozumi K, Yoshimoto K, Matsuda M, Matsumura A, Hirose Y, Tokuyama T, Kumabe T, Ueki K, Narita Y, Shibui S, Totoki Y, Shibata T, Nakazato Y, Nishikawa R, Matsutani M, Ichimura K; Intracranial Germ Cell Tumor Genome Analysis Consortium (the iGCT Consortium).

Neuropathol Appl Neurobiol. 2019 Jun 10. doi: 10.1111/nan.12570. [Epub ahead of print]

PMID:
31179566
25.

The feasibility of contrast-enhanced spectral mammography immediately after contrast-enhanced CT.

Okada N, Tatsugami F, Sugai M, Okita I, Ito M, Ohtani S, Ichimura K, Urashima M, Awai K.

Radiol Phys Technol. 2019 Sep;12(3):277-282. doi: 10.1007/s12194-019-00518-6. Epub 2019 Jun 5.

PMID:
31165975
26.

Diagnostic Performance of a Temporal Artery Biopsy for the Diagnosis of Giant Cell Arteritis in Japan-A Single-center Retrospective Cohort Study.

Oiwa H, Ichimura K, Hosokawa Y, Araki K, Funaki M, Kawashima M, Mihara H, Kimura N.

Intern Med. 2019 Sep 1;58(17):2451-2458. doi: 10.2169/internalmedicine.2788-19. Epub 2019 May 22.

27.

Anticancer effects of a non-narcotic opium alkaloid medicine, papaverine, in human glioblastoma cells.

Inada M, Shindo M, Kobayashi K, Sato A, Yamamoto Y, Akasaki Y, Ichimura K, Tanuma SI.

PLoS One. 2019 May 17;14(5):e0216358. doi: 10.1371/journal.pone.0216358. eCollection 2019.

28.

Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts.

Takahashi M, Miki S, Fujimoto K, Fukuoka K, Matsushita Y, Maida Y, Yasukawa M, Hayashi M, Shinkyo R, Kikuchi K, Mukasa A, Nishikawa R, Tamura K, Narita Y, Hamada A, Masutomi K, Ichimura K.

Cancer Sci. 2019 Jul;110(7):2247-2257. doi: 10.1111/cas.14067. Epub 2019 Jun 10.

29.

Three-dimensional architecture of pericardial nephrocytes in Drosophila melanogaster revealed by FIB/SEM tomography.

Kawasaki Y, Matsumoto A, Miyaki T, Kinoshita M, Kakuta S, Sakai T, Ichimura K.

Cell Tissue Res. 2019 Nov;378(2):289-300. doi: 10.1007/s00441-019-03037-3. Epub 2019 May 14.

PMID:
31089884
30.

High-grade glioneuronal tumor with an ARHGEF2-NTRK1 fusion gene.

Kurozumi K, Nakano Y, Ishida J, Tanaka T, Doi M, Hirato J, Yoshida A, Washio K, Shimada A, Kohno T, Ichimura K, Yanai H, Date I.

Brain Tumor Pathol. 2019 Jul;36(3):121-128. doi: 10.1007/s10014-019-00345-y. Epub 2019 Apr 22.

PMID:
31011918
31.

Anatomic characterization of the femoral nutrient artery: Application to fracture and surgery of the femur.

Kawasaki Y, Kinose S, Kato K, Sakai T, Ichimura K.

Clin Anat. 2019 Apr 22. doi: 10.1002/ca.23390. [Epub ahead of print]

PMID:
31008535
32.

PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors.

Tateishi K, Nakamura T, Juratli TA, Williams EA, Matsushita Y, Miyake S, Nishi M, Miller JJ, Tummala SS, Fink AL, Lelic N, Koerner MVA, Miyake Y, Sasame J, Fujimoto K, Tanaka T, Minamimoto R, Matsunaga S, Mukaihara S, Shuto T, Taguchi H, Udaka N, Murata H, Ryo A, Yamanaka S, Curry WT, Dias-Santagata D, Yamamoto T, Ichimura K, Batchelor TT, Chi AS, Iafrate AJ, Wakimoto H, Cahill DP.

Clin Cancer Res. 2019 Jul 15;25(14):4375-4387. doi: 10.1158/1078-0432.CCR-18-4144. Epub 2019 Apr 11.

PMID:
30975663
33.

Review of ependymomas: assessment of consensus in pathological diagnosis and correlations with genetic profiles and outcome.

Sasaki A, Hirato J, Hirose T, Fukuoka K, Kanemura Y, Hashimoto N, Kodama Y, Ichimura K, Sakamoto H, Nishikawa R.

Brain Tumor Pathol. 2019 Apr;36(2):92-101. doi: 10.1007/s10014-019-00338-x. Epub 2019 Mar 30.

PMID:
30929114
34.

TERT promoter mutation as a diagnostic marker for diffuse gliomas.

Ichimura K.

Neuro Oncol. 2019 Mar 18;21(4):417-418. doi: 10.1093/neuonc/noz025. No abstract available.

35.

Protein Phosphatases-A Touchy Enemy in the Battle Against Glioblastomas: A Review.

Tomiyama A, Kobayashi T, Mori K, Ichimura K.

Cancers (Basel). 2019 Feb 19;11(2). pii: E241. doi: 10.3390/cancers11020241. Review.

36.

Signal transduction pathways and resistance to targeted therapies in glioma.

Tomiyama A, Ichimura K.

Semin Cancer Biol. 2019 Oct;58:118-129. doi: 10.1016/j.semcancer.2019.01.004. Epub 2019 Jan 24. Review.

PMID:
30685341
37.

Genome-wide DNA methylation profiling shows molecular heterogeneity of anaplastic pleomorphic xanthoastrocytoma.

Nakamura T, Fukuoka K, Nakano Y, Yamasaki K, Matsushita Y, Yamashita S, Ikeda J, Udaka N, Tanoshima R, Shiba N, Tateishi K, Yamanaka S, Yamamoto T, Hirato J, Ichimura K.

Cancer Sci. 2019 Feb;110(2):828-832. doi: 10.1111/cas.13903. Epub 2019 Jan 4.

38.

Disruption of the MAMP-Induced MEKK1-MKK1/MKK2-MPK4 Pathway Activates the TNL Immune Receptor SMN1/RPS6.

Takagi M, Hamano K, Takagi H, Morimoto T, Akimitsu K, Terauchi R, Shirasu K, Ichimura K.

Plant Cell Physiol. 2019 Apr 1;60(4):778-787. doi: 10.1093/pcp/pcy243.

PMID:
30590768
39.

Morphological Processes of Foot Process Effacement in Puromycin Aminonucleoside Nephrosis Revealed by FIB/SEM Tomography.

Ichimura K, Miyaki T, Kawasaki Y, Kinoshita M, Kakuta S, Sakai T.

J Am Soc Nephrol. 2019 Jan;30(1):96-108. doi: 10.1681/ASN.2018020139. Epub 2018 Dec 4.

40.

Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors.

Fukuoka K, Kanemura Y, Shofuda T, Fukushima S, Yamashita S, Narushima D, Kato M, Honda-Kitahara M, Ichikawa H, Kohno T, Sasaki A, Hirato J, Hirose T, Komori T, Satomi K, Yoshida A, Yamasaki K, Nakano Y, Takada A, Nakamura T, Takami H, Matsushita Y, Suzuki T, Nakamura H, Makino K, Sonoda Y, Saito R, Tominaga T, Matsusaka Y, Kobayashi K, Nagane M, Furuta T, Nakada M, Narita Y, Hirose Y, Ohba S, Wada A, Shimizu K, Kurozumi K, Date I, Fukai J, Miyairi Y, Kagawa N, Kawamura A, Yoshida M, Nishida N, Wataya T, Yamaoka M, Tsuyuguchi N, Uda T, Takahashi M, Nakano Y, Akai T, Izumoto S, Nonaka M, Yoshifuji K, Kodama Y, Mano M, Ozawa T, Ramaswamy V, Taylor MD, Ushijima T, Shibui S, Yamasaki M, Arai H, Sakamoto H, Nishikawa R, Ichimura K; Japan Pediatric Molecular Neuro-Oncology Group (JPMNG).

Acta Neuropathol Commun. 2018 Dec 4;6(1):134. doi: 10.1186/s40478-018-0630-1.

41.

Nanoparticle-Mediated Targeting of Pitavastatin to Small Pulmonary Arteries and Leukocytes by Intravenous Administration Attenuates the Progression of Monocrotaline-Induced Established Pulmonary Arterial Hypertension in Rats.

Ichimura K, Matoba T, Koga JI, Nakano K, Funamoto D, Tsutsui H, Egashira K.

Int Heart J. 2018 Nov 28;59(6):1432-1444. doi: 10.1536/ihj.17-683. Epub 2018 Oct 25.

42.

Identification of a novel KLC1-ROS1 fusion in a case of pediatric low-grade localized glioma.

Nakano Y, Tomiyama A, Kohno T, Yoshida A, Yamasaki K, Ozawa T, Fukuoka K, Fukushima H, Inoue T, Hara J, Sakamoto H, Ichimura K.

Brain Tumor Pathol. 2019 Jan;36(1):14-19. doi: 10.1007/s10014-018-0330-3. Epub 2018 Oct 22. Review.

PMID:
30350109
43.

Frequent false-negative immunohistochemical staining with IDH1 (R132H)-specific H09 antibody on frozen section control slides: a potential pitfall in glioma diagnosis.

Yoshida A, Satomi K, Ohno M, Matsushita Y, Takahashi M, Miyakita Y, Hiraoka N, Narita Y, Ichimura K.

Histopathology. 2019 Jan;74(2):350-354. doi: 10.1111/his.13756. Epub 2018 Dec 5.

PMID:
30221786
44.

Lesion location implemented magnetic resonance imaging radiomics for predicting IDH and TERT promoter mutations in grade II/III gliomas.

Arita H, Kinoshita M, Kawaguchi A, Takahashi M, Narita Y, Terakawa Y, Tsuyuguchi N, Okita Y, Nonaka M, Moriuchi S, Takagaki M, Fujimoto Y, Fukai J, Izumoto S, Ishibashi K, Nakajima Y, Shofuda T, Kanematsu D, Yoshioka E, Kodama Y, Mano M, Mori K, Ichimura K, Kanemura Y.

Sci Rep. 2018 Aug 6;8(1):11773. doi: 10.1038/s41598-018-30273-4.

45.

Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas.

Yamauchi T, Ohno M, Matsushita Y, Takahashi M, Miyakita Y, Kitagawa Y, Kondo E, Tsushita N, Satomi K, Yoshida A, Ichimura K, Narita Y.

Brain Tumor Pathol. 2018 Jul;35(3):148-158. doi: 10.1007/s10014-018-0321-4. Epub 2018 Jun 19.

PMID:
29922974
46.

Involvement of Intracellular Cholesterol in Temozolomide-Induced Glioblastoma Cell Death.

Yamamoto Y, Sasaki N, Kumagai K, Takeuchi S, Toyooka T, Otani N, Wada K, Narita Y, Ichimura K, Namba H, Mori K, Tomiyama A.

Neurol Med Chir (Tokyo). 2018 Jul 15;58(7):296-302. doi: 10.2176/nmc.ra.2018-0040. Epub 2018 Jun 13. Review.

47.

The p53 activator overcomes resistance to ALK inhibitors by regulating p53-target selectivity in ALK-driven neuroblastomas.

Miyazaki M, Otomo R, Matsushima-Hibiya Y, Suzuki H, Nakajima A, Abe N, Tomiyama A, Ichimura K, Matsuda K, Watanabe T, Ochiya T, Nakagama H, Sakai R, Enari M.

Cell Death Discov. 2018 May 10;4:56. doi: 10.1038/s41420-018-0059-0. eCollection 2018.

48.

Concomitant administration of radiation with eribulin improves the survival of mice harboring intracerebral glioblastoma.

Miki S, Imamichi S, Fujimori H, Tomiyama A, Fujimoto K, Satomi K, Matsushita Y, Matsuzaki S, Takahashi M, Ishikawa E, Yamamoto T, Matsumura A, Mukasa A, Nishikawa R, Masutomi K, Narita Y, Masutani M, Ichimura K.

Cancer Sci. 2018 Jul;109(7):2275-2285. doi: 10.1111/cas.13637. Epub 2018 Jun 19.

49.

IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis.

Otani R, Uzuka T, Higuchi F, Matsuda H, Nomura M, Tanaka S, Mukasa A, Ichimura K, Kim P, Ueki K.

Cancer Sci. 2018 Jul;109(7):2327-2335. doi: 10.1111/cas.13635. Epub 2018 Jun 15.

50.

Elevated TERT Expression in TERT-Wildtype Adult Diffuse Gliomas: Histological Evaluation with a Novel TERT-Specific Antibody.

Masui K, Komori T, Kato Y, Masutomi K, Ichimura K, Ogasawara S, Kaneko MK, Oki H, Suzuki H, Nitta M, Maruyama T, Muragaki Y, Kawamata T, Sawada T, Shibata N.

Biomed Res Int. 2018 Mar 5;2018:7945845. doi: 10.1155/2018/7945845. eCollection 2018.

Supplemental Content

Loading ...
Support Center